{"nctId":"NCT01112306","briefTitle":"ACT-293987 in Pulmonary Arterial Hypertension","startDateStruct":{"date":"2010-07-07","type":"ACTUAL"},"conditions":["Pulmonary Arterial Hypertension"],"count":709,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: ACT-293987"]}],"interventions":[{"name":"ACT-293987","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who participated to the double-blind study AC-065A302 and either had a morbidity event or had completed the study as scheduled per protocol.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients who have started receiving prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostinil, iloprost, beraprost) since the last study drug intake in AC-065A302/GRIPHON.\n* Severe hepatic impairment (Child-Pugh C).\n* Females who are pregnant or who plan to become pregnant during the study, or are breastfeeding.\n* Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence, or psychiatric disease.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation","description":"An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"684","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation","description":"An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"420","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention","description":"An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Alive Participants","description":"Percentage of alive participants were analyzed using Kaplan-Meier (KM) estimates.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":420,"n":709},"commonTop":["Headache","Diarrhoea","Nausea","Pain in Jaw","Oedema Peripheral"]}}}